Pneumococcal infection

This trial tests a new pneumococcal vaccine, called PG4, in adults aged 18 to 49. Researchers compare three batches of PG4 to each other and to the current vaccine, Prevnar 20, to see if they produce similar immune responses and are equally safe. Participants receive one injectio…

This study tests a new vaccine to protect babies against pneumococcal infections, which can cause pneumonia and meningitis. About 500 healthy infants will receive either the new vaccine or an existing one. Researchers will check if the new vaccine triggers a strong immune respons…

This study tests whether a pneumococcal vaccine (Pneumosil) can produce a strong immune response in children aged 6-59 months who are hospitalised with severe acute malnutrition. Half the children will receive the pneumococcal vaccine, and the other half will receive a typhoid va…

Researchers are testing an experimental antibody called EA5 in adults with generalized myasthenia gravis whose blood contains antibodies against the acetylcholine receptor and who have not tried complement inhibitor drugs. EA5 targets complement protein C5, part of the immune cas…

This early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new v…

This study tests whether a simple WhatsApp message reminding people turning 65 in Chile to get their free pneumococcal vaccine can increase vaccination rates. Over 43,000 adults will be randomly assigned to receive the reminder or not, and researchers will track who gets vaccinat…

This large trial will study whether flu and pneumonia vaccines can reduce serious flare-ups and medical costs in people aged 45-80 with COPD. About 7,000 participants will be split into four groups: flu vaccine, pneumonia vaccine, both, or no vaccine. Researchers will track lung …

This study compares two schedules (2+1 vs 3+1 doses) of a 13-valent pneumococcal vaccine in 210 healthy infants starting at 2 months old. Researchers will measure antibody levels and track side effects to find the best way to prevent pneumococcal infections.

Researchers in Panama survey adults age 50 and older about pneumococcal disease and the PCV21 vaccine, which protects against pneumonia and other serious infections. One group covers ages 50 to 64; another covers adults 65 and older plus a caregiver who helps them. Each person an…

This study follows 100 infants who received a pneumococcal vaccine in an earlier trial. Researchers will take a small blood sample to measure antibody levels one and two years after vaccination. The goal is to see how long protection against pneumococcal infections lasts. No new …